We evaluated possible associations between the expression of PHLDA1, SPRY4, EPHA2, and DUSP4 and MEK/ERK pathway activity in 20 ovarian cancer cell lines (Figure 2). This evidence concerns the gene MAP2K7 and ovarian carcinoma.